Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 15.4K citations

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 1.1K citations

Human Somatostatin Receptor, Affinity Profiles, Somatostatin Radiotracers +6

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 468 citations

Clinical Translation, Medicine, Pathology +2

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Roelf Valkema, Marion de Jong, Willem H. Bakker et al. · Seminars in Nuclear Medicine · 2002 · 430 citations

Medicine, Radionuclide Therapy, Peptide Library +8

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

Christian Waldherr, Misha Pless, Helmut R. Maëcke et al. · Annals of Oncology · 2001 · 394 citations

Neuroendocrine Tumours, Medicine, Pharmacology +7